Pharmacokinetics of several subcutaneous doses of erythropoietin: Potential implications for blood transfusion

Clinical and Experimental Pharmacology and Physiology

Volumn 27, Issue 3, 2000, Pages 179-184

  Sans, T ^a,c   Joven, J ^a   Vilella, E ^a   Masdeu, G ^a   Farre M ^b  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c Hospital Comarcal Mora d'Ebre   (Spain)

Author keywords

Autologous blood transfusion; Erythropoietin; Pharmacokinetics; Subcutaneous

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; BLOOD AUTOTRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; ELECTIVE SURGERY; FEMALE; HUMAN; MALE; RETICULOCYTE COUNT;

EID: 0034112820     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2000.03221.x     Document Type: Article

References (31)

1. 1. Wasman J, Goodnough LT. Autologous blood donation for elective surgery. Effect on physician transfusion behavior. JAMA 1987; 258: 3135-7.
2. 2. Renner SW, Howanitz PJ, Bachner P. Preoperative autologous blood donation in 612 hospitals. A College of American Pathologists Q-probes study of quality issues in transfusion practice. Arch. Pathol. Lab. Med. 1992; 116: 613-19.
3. 3. Goodnough LT, Shafron D, Marcus RE. Impact of preoperative autologous blood donation on orthopaedic surgical practice. Vox Sang. 1990; 59: 65-9.
4. 4. Toy PTCY, Menozzi D, Strauss RG, Stehling LC, Kruskall M, Ahn DK, Efficacy of preoperative donation of blood for autologous use in radical prostatectomy. Transfusion 1993; 33: 721-4.
5. 5. Goodnough LT, Vizmeg K, Verbrugge D. The impact of autologous blood ordering and blood procurement practices on allogeneic blood exposure in elective orthopedic surgery patients. Am. J. Clin. Pathol. 1994; 101: 354-7.
6. 6. Goodnough LT, Rudnick S, Price TH et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N. Engl. J. Med. 1989; 321: 1163-8.
7. 7. Canadian Orthopedic Perioperative Erythropoietin Study Group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 1993; 341: 1227-32.
8. 8. Faris PM, Ritter MA, Abels RI for the American Erythropoietin Study groups. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. J. Bone Joint Surg. 1996; 78A: 62-72.
9. 9. Biesma DH, Marx JJ, Kraaijenhagen RJ, Franke W, Messinger D, Van de Wiel A. Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietin. Lancet 1994; 344: 367-70.
10. 10. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N. Engl. J. Med. 1997; 336: 933-8.
11. 11. Zachee P. Controversies in selection of epoetin dosages. Issues and answers. Drugs 1995; 49: 536-47.
12. 12. Salmonson T, Danielson BG, Wikström B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br. J. Clin. Pharmacol. 1990; 29: 709-13.
13. 13. Hayashi J, Kumon K, Takanashi S et al. Subcutaneous administration of recombinant human erythropoietin before cardiac surgery: A double-blind, multicenter trial in Japan. Transfusion 1994; 34: 142-6.
14. 14. Kulier AH, Gombotz H, Fuchs G, Vuckovic U, Metzler H. Subcutaneous recombinant human erythropoietin and autologous blood donation before coronary artery bypass surgery. Anesth. Analg. 1993; 76: 102-6.
15. 15. Goldberg MA, McCutchen JW, Jove M et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am. J. Orthopedics 1996; 25: 544-52.
16. 16. Sans T, Bofill C, Joven J et al. Effectiveness of very low doses of subcutaneous recombinant human erythropoietin in facilitating autologous blood donation before orthopedic surgery. Transfusion 1996; 36: 822-6.
17. 17. Bofill C, Joven J, Bages J et al. Response to repeated phlebotomies in patients with non-insulin-dependent diabetes mellitus. Metabolism 1994; 43: 614-20.
18. 18. Faulds D, Sorkin EM. Epoetin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Drugs 1989; 38: 863-99.
19. 19. Braun A, Ding R, Seidel C, Fies T, Kurtz A, Scharer K. Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure. Pediatr. Nephrol. 1993; 7: 61-4.
20. 20. Yamazaki C, Watanabe Y, Sakamoto N. Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients. Jpn. J. Nephrol. 1993; 35: 1233-42.
21. 21. Schouten JP, Voorhorst G, Helbing AR, Jansen JW, Diderich P, Op de Hoek CT. Pharmacokinetics of epoetin in haemodialysis patients after subcutaneous administration: Influence of chronic treatment. Pharm. World Sci. 1993; 15: 251-6.
22. 22. Jensen JD, Madsen JK, Jensen LW, Pedersen EB. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. J. Am. Soc. Nephrol. 1994; 5: 177-85.
23. 23. Macdougall IC, Jones JM, Robinson MI, Miles JB, Coles GA, Williams JD. Subcutaneous erythropoietin therapy: Comparision of three different sites of injection. Contrib. Nephrol. 1991; 88: 152-6.
24. 24. Jensen JD, Jensen LW, Madsen JK. The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur. J. Clin. Pharmacol. 1994; 46: 333-7.
25. 25. Granolleras C, Branger B, Beau MC, Deschodt G, Alsabadani B, Shaldon S. Experience with daily self-administered subcutaneous erythropoietin. Contrib. Nephrol. 1989; 76: 143-8.
26. 26. Biesma DH, Kraaijenhagen RJ, Poortman J, Marx JJM, Van De Wiel A. The effect of oral iron supplementation on erythropoiesis in autologous blood donors. Transfusion 1992; 32: 162-5.
27. 27. McMahon FG, Vargas R, Ryan M et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76: 1718-22.
28. 28. Flaharty KK, Caro J, Erslev A et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin. Pharmacol. Ther. 1990; 47: 557-64.
29. 29. Souillard A, Audran M, Bressolle F, Dgareau R, Duvallet A, Chanal JL. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control. Br. J. Clin. Pharmacol. 1996; 42: 355-64.
30. 30. Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin. Pharmacol. Ther. 1998; 64: 412-23.
31. 31. Kampf D, Eckardt KU, Fisher HC, Schmalisch C, Ehmer B, Schostak M. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 1992; 61: 393-8.